Comments

Sarepta Therapeutics

Q: What sector and industry does Sarepta Therapeutics (SRPT) operate in?

Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

SRPTNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

$106.28

-2.13-1.96%

At close: -

$106.00

-0.28-0.26%

After Hours: 5:43 PM EDT

Q4 2024 Earnings in 4 days from now on Wed Feb 26th, after the market close

Conference call scheduled in 4 days at 16:30 PM Click to view the webcast

Sarepta Therapeutics (SRPT) Forecast

News Earnings Sarepta Therapeutics (SRPT) Options Guidance Dividends Analyst Ratings Insider Trades Government Trades Short Interest

Edge Rankings

Want to View Edge Rankings?

Unlock The Hidden Results With Your Benzinga Account Now.

Get Started

Sarepta Therapeutics (NASDAQ:SRPT) Stock Quotes, Forecast and News Summary

Sarepta Therapeutics Stock (NASDAQ: SRPT) stock price, news, charts, stock research, profile.

Open	$109.50
Close	$106.28
Volume / Avg.	709.35K / 869.58K
Day Range	$106.02 - $110.00
52 Wk Range	101.15 - 173.25
Market Cap	$10.13B
P/E Ratio	70.40
Dividend Yield	-
Exchange	NASDAQ
RSI	35
Short Interest	5.53%
Days to Cover	5.74

Recent News

Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?

Shares of biotech company Solid Biosciences (NASDAQ:SLDB) skyrocketed on Feb. 18 after the firm released key clinical data. Solid shares ended the day up nearly 32%. So, what information came out resulting in this

MarketBeat

Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years

Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement and minimal muscle pathology progression.

Vandana Singh

Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development (CORRECTED)

Solid Biosciences advances gene therapies for muscular and cardiac diseases, gaining FDA clearance for SGT-212 and targeting key 2025 milestones.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Nov 24

Dec 24

Jan

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.1

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$109.50
Close	$106.28
Volume / Avg.	709.35K / 869.58K
Day Range	$106.02 - $110.00
52 Wk Range	101.15 - 173.25
Market Cap	$10.13B
P/E Ratio	70.40
Dividend Yield	-
Exchange	NASDAQ
RSI	35
Short Interest	5.53%
Days to Cover	5.74

About Sarepta Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Sarepta Therapeutics (SRPT) stock?

You can purchase shares of Sarepta Therapeutics (NASDAQ:SRPT) through any online brokerage.

View our list of the best stock brokerages

Who are Sarepta Therapeutics (SRPT) competitors?

Other companies in Sarepta Therapeutics’s space includes: BeiGene (NASDAQ:ONC), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX), Amgen (NASDAQ:AMGN) and United Therapeutics (NASDAQ:UTHR).

What is the forecast, or price target, for Sarepta Therapeutics (SRPT) stock?

Sarepta Therapeutics has a consensus price target of $171.85.

What is the current price for Sarepta Therapeutics (SRPT)?

The stock price for Sarepta Therapeutics (NASDAQ: SRPT) is $106 last updated February 21, 2025 at 5:43 PM EST.

Does Sarepta Therapeutics (SRPT) pay a dividend?

There are no upcoming dividends for Sarepta Therapeutics.

When is Sarepta Therapeutics (NASDAQ:SRPT) reporting earnings?

Sarepta Therapeutics’s Q1 earnings are confirmed for Wednesday, April 30, 2025.

Is Sarepta Therapeutics (SRPT) going to split?

There is no upcoming split for Sarepta Therapeutics.

What sector and industry does Sarepta Therapeutics (SRPT) operate in?

Sarepta Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.